Zusammenfassung
Die Resektion kolorektaler Lebermetastasen (CRLM) im Rahmen eines multimodalen Therapiekonzeptes ist ein allgemein akzeptierter, potenziell kurativer Behandlungsansatz. Trotz der Tatsache, dass die Leberchirurgie eine Überlebensverlängerung für die Patienten bei guter Lebensqualität darstellt, wird diese Therapieoption bei weitem nicht allen Patienten angeboten. Der Beitrag fasst Ergebnisse der Leberresektion bei CRLM-Patienten zusammen und diskutiert Gründe für die unterschiedliche Einschätzung der Resektabilität selbst durch erfahrene Leberchirurgen. Die Komplexität der Behandlung wird exemplarisch an einem Fall aufgezeigt.
Abstract
The resection of colorectal liver metastases (CRLM) within the framework of a multimodal treatment concept is a generally accepted and potentially curative treatment approach. Despite the fact that liver surgery represents a survival extension for patients with a good quality of life, this treatment option is offered to nowhere near all patients. This article summarizes the results of liver resection for CRLM patients and discusses the reasons for the different estimations of resectability even by experienced liver surgeons. The complexity of the treatment is exemplarily shown based on a case report.
Literatur
Adam R, Laurent A, Azoulay D et al (2000) Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 232:777–785. https://doi.org/10.1097/00000658-200012000-00006
Albertsmeier M, Riedl K, Stephan A‑J et al (2020) Improved survival after resection of colorectal liver metastases in patients with unresectable lung metastases. HPB 22:368–375. https://doi.org/10.1016/j.hpb.2019.07.004
Azoulay D, Castaing D, Adam R et al (2000) Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 231:480–486
Brouquet A, Abdalla EK, Kopetz S et al (2011) High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29:1083–1090. https://doi.org/10.1200/jco.2010.32.6132
Capobianco I, Strohäker J, Penna AD et al (2019) Präkonditionierung der Leber. Chirurg 90:542–547. https://doi.org/10.1007/s00104-019-0926-0
Creasy JM, Sadot E, Koerkamp BG et al (2018) Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 163:1238–1244. https://doi.org/10.1016/j.surg.2018.01.004
Filmann N, Walter D, Schadde E et al (2019) Mortality after liver surgery in Germany. Br J Surg 106:1523–1529. https://doi.org/10.1002/bjs.11236
Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311–1319. https://doi.org/10.1093/annonc/mdi246
Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47. https://doi.org/10.1016/s1470-2045(09)70330-4
Guiu B, Quenet F, Escal L et al (2017) Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function. Eur Radiol 27:3343–3352. https://doi.org/10.1007/s00330-017-4744-9
Hackl C, Neumann P, Gerken M et al (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810. https://doi.org/10.1186/1471-2407-14-810
Huiskens J, Bolhuis K, Engelbrecht MR et al (2019) Outcomes of resectability assessment of the Dutch colorectal cancer group liver metastases expert panel. J Am Coll Surg 229:523–532.e2. https://doi.org/10.1016/j.jamcollsurg.2019.08.1445
Ignatavicius P, Oberkofler CE, Chapman WC et al (2020) Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice? Ann Surg 272:715–722. https://doi.org/10.1097/sla.0000000000004331
Lordan JT, Karanjia ND, Quiney N et al (2009) A 10-year study of outcome following hepatic resection for colorectal liver metastases—the effect of evaluation in a multidisciplinary team setting. European J Surg Oncol 35:302–306. https://doi.org/10.1016/j.ejso.2008.01.028
Mohammad WM, Martel G, Mimeault R et al (2012) Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB 14:291–297. https://doi.org/10.1111/j.1477-2574.2012.00440.x
Nathan H, Bridges JF, Cosgrove DP et al (2012) Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. Ann Surg Oncol 19:3668–3676. https://doi.org/10.1245/s10434-012-2564-3
Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215. https://doi.org/10.1016/s1470-2045(13)70447-9
Nordlinger B, Sorbye H, Glimelius B, Poston GJ (2008) ScienceDirect.com—The Lancet—perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):P1007–1016. https://doi.org/10.1016/S0140-6736(08)60455-9
Oldhafer KJ, Stavrou GA, van Gulik TM (2016) ALPPS—where do we stand, where do we go?: eight recommendations from the first international expert meeting. Ann Surg 263:839–841. https://doi.org/10.1097/sla.0000000000001633
Petrowsky H, Linecker M, Raptis DA et al (2020) First long-term oncologic results of the ALPPS procedure in a large cohort of patients with colorectal liver metastases. Ann Surg 272:793–800. https://doi.org/10.1097/sla.0000000000004330
Poston GJ, Tait D, O’Connell S et al (2011) Diagnosis and management of colorectal cancer: summary of NICE guidance
Rahbari NN, Birgin E, Bork U et al (2021) Anterior approach vs conventional hepatectomy for resection of colorectal liver metastasis. JAMA Surg. https://doi.org/10.1001/jamasurg.2020.5050
Renfro LA, Goldberg RM, Grothey A et al (2017) Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the aide et recherche en cancérologie digestive database. J Clin Oncol 35:1929–1937. https://doi.org/10.1200/jco.2016.71.5771
Sawada Y, Sahara K, Endo I et al (2020) Long-term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: A multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 27:810–818. https://doi.org/10.1002/jhbp.810
Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastases. World J Surg 19:59–71
Stintzing S, Miller-Phillips L, Modest DP et al (2017) Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE‑3 (AIO KRK-0306) study. Eur J Cancer 79:50–60. https://doi.org/10.1016/j.ejca .2017.03.023
Strohäker J, Königsrainer A, Nadalin S (2019) Rolle des Radiologen in der Chirurgie kolorektaler Lebermetastasen. Radiologe 59:791–798. https://doi.org/10.1007/s00117-019-0577-7
Tiernan J, Briggs C, Irving G et al (2010) Evaluation of the introduction of a standardised protocol for the staging and follow-up of colorectal cancer on resection rates for liver metastases. Ann R Coll Surg Engl 92:225–230. https://doi.org/10.1308/003588410x12628812458419
Tomlinson JS, Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580. https://doi.org/10.1200/jco.2007.11.0833
Uppal A, Smieliauskas F, Sharma MR et al (2020) Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer 126:281–292. https://doi.org/10.1002/cncr.32529
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
G.A. Stavrou, O. Ghamarnejad und K.J. Oldhafer geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Stavrou, G.A., Ghamarnejad, O. & Oldhafer, K.J. Warum werden zu wenige Patienten mit kolorektalen Lebermetastasen zur Resektion vorgestellt?. Chirurg 92, 736–741 (2021). https://doi.org/10.1007/s00104-021-01363-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-021-01363-3